{"cluster": 65, "subcluster": 4, "abstract_summ": " SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor2,4-6 . The antibodies identified here may be candidates for the development of SARS . The discovery and development of virus-neutralizing monoclonal antibodies could be one approach to treat or prevent infection ."}